Summary
Signal counts
Assets tracked: 5
Watchlist assets: 3
Registry stop assets: 0
Sponsor overview
Tianjin Medical University Cancer Institute and Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05853172 | https://clinicaltrials.gov/study/NCT05806671 | https://clinicaltrials.gov/study/NCT05490719 | https://clinicaltrials.gov/study/NCT05799820 | https://clinicaltrials.gov/study/NCT07153965 | https://clinicaltrials.gov/study/NCT07172412
Assets
Linked programs
- AK104: Timeline Staleness Signal (3/5)
- Dalpiciclib: Timeline Staleness Signal (4/5)
- QL1706: Timeline Staleness Signal (3/5)
- Sacituzumab Tirumotecan plus Tagitanlimab: Low Signal (1/5)
- Selinexor: Low Signal (1/5)